B-MS/Sanofi face Plavix injury law suits
The first personal injury lawsuit against the makers of Plavix (clopidogrel), Bristol-Myers Squibb and Sanofi-Aventis, has been filed. Among the allegations are misleading the public and hiding the risks of the popular blood thinning drug, Plavix.
The law suit, filed on behalf of an individual injured by Plavix, comes just days after third-party payers announced they had filed a class action against the companies, alleging that Plavix causes much higher risks of heart attack, stroke, internal bleeding and death than previously reported. The suit further alleges that the companies knew this information and had been warned repeatedly by the Food and Drug Administration to stop its misleading advertising and promotional practices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze